GlassScriptPhysician profile
Marissa Crofut
NPI 1952959546
$1,670.52
in general payments reported to CMS, 2019-2025
31 companies · $561 in 2025
The $561 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.32 · 2022: $187 · 2023: $312 · 2024: $559 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $151.89 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Vertex Pharmaceuticals Incorporated | $120.30 | 2025 | |
| Kerecis Limited | $114.37 | 2023-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Surgiclose |
| Astrazeneca Pharmaceuticals LP | $110.66 | 2021-2024 | Lynparza |
| Medtronic, INC. | $108.76 | 2021-2025 | Pteye Parathyroid Detection System, Signia |
| Incyte Corporation | $91.68 | 2024-2025 | Monjuvi, Jakafi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $87.89 | 2022-2023 | Ninlaro |
| Lilly USA, LLC | $75.21 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Janssen Biotech, INC. | $73.94 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Davol INC. | $72.41 | 2024 | Phasix Mesh |
| Jazz Pharmaceuticals INC. | $69.73 | 2022-2025 | |
| Integra Lifesciences Corporation | $53.13 | 2024-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Astellas Pharma US INC | $51.20 | 2021-2024 | Padcev |
| Genentech USA, INC. | $48.52 | 2023 | Perjeta, Phesgo, Columvi |
| Regeneron Healthcare Solutions, INC. | $46.34 | 2023-2025 | Libtayo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $43.75 | 2023-2024 | Krazati |
| Stemline Therapeutics INC. | $37.29 | 2023-2025 | Orserdu |
| Merck Sharp & Dohme LLC | $33.96 | 2022-2024 | Keytruda |
| Olympus America INC. | $28.51 | 2024 | Olympus |
| Solventum Corporation | $28.12 | 2025 | Prevena, V.A.C.Ulta |
| Amgen INC. | $23.22 | 2023 | Kyprolis |
| Smith+Nephew, INC. | $22.91 | 2025 | Stravix, Grafix |
| Progenics Pharmaceuticals, INC. | $22.26 | 2023 | Pylarify |
| Sobi, INC | $22.16 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.52 | 2025 | |
| Taiho Oncology, INC. | $20.52 | 2025 | |
| Agios Pharmaceuticals, INC. | $20.43 | 2025 | Pyrukynd |
| Daiichi Sankyo INC. | $19.90 | 2024 | Enhertu |
| Gilead Sciences, INC. | $17.03 | 2022 | |
| Servier Pharmaceuticals LLC | $16.97 | 2024 | |
| Coherus Oncology, INC. | $15.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Crofut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.